CompletedNCT00177164
Long-acting risperidone compared with oral antipsychotics in bipolarity I
Medication studyAges 18–70United States
Understand this study
Who was this study for?
This study was for people with bipolarity. Listed age limits: 18 years to 70 years. Other eligibility criteria applied.
- Listed locations
- Bridgeville and 3 more locationsSee all locations and recruitment
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Study information
Study start dateNovember 2003
- Recruitment status
- Completed
- Enrollment listed in the registry
- 50
- Sponsor
- University of Pittsburgh
- Sponsor type
- University
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- United States
- Age range
- From 18 Years to 70 Years
- Official registry ID
- NCT00177164
- Official title
Show the full official title
A Random Assignment,Parallel Group, Open Label Comparison of Clinical Outcomes and Resource Utilization Among Bipolar Disorder Patients Receiving Either Long Acting Injectable Risperidone Microspheres (Risperdal Consta® ) or Other Second Generation Oral Antipsychotic Agents: A 15 Month Study
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Bridgeville · DuBois · McKeesport
1 more locations
- Pittsburgh
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is University of Pittsburgh, a university.
Did this study involve medication?
Yes. The study involved medication, including Injectable Risperidone (Consta) or oral antipsychotic.
Who was this study for?
This study was for people with bipolarity. Listed age limits: 18 years to 70 years. Other eligibility criteria applied.
